RxDoctor Payments Data

Alicia Noto, NP

Nurse Practitioner · West Islip, NYNPI 1265605505

Payments from drug & device makers

$2,671in general payments, 2019–2025

Across 95 payments — averaging $28.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$501
  • Merck$405
  • AstraZeneca$381
  • Abbott$209
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$173
  • Daiichi Sankyo Inc.$153
  • plus $849 from 19 others

What the payments were for

  • Food & beverage$2,671100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,671 in reported general payments places this provider in the 90th percentile of 4,112 nurse practitioner providers in New York.

See all nurse practitioner providers in New York

Medicare billing

Part B allowed, 2024
$65,356
Medicare patients
333
Services billed
632

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban446$544,929
EntrestoSacubitril/Valsartan171$251,319
XareltoRivaroxaban165$227,713
Repatha SureclickEvolocumab108$105,705
JardianceEmpagliflozin68$94,815
FarxigaDapagliflozin Propanediol74$91,470
BrilintaTicagrelor68$65,968
Praluent PenAlirocumab44$43,247
Metoprolol Succinate1,180$20,374
VascepaIcosapent Ethyl14$9,654
Atorvastatin Calcium772$7,530
Ranolazine ErRanolazine41$6,830
Diltiazem 24hr Er (Cd)Diltiazem Hcl120$6,608
Valsartan213$6,435
Rosuvastatin Calcium419$5,286

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$104$544,929446 claims
NovartisEntresto$29$251,319171 claims
Johnson & JohnsonXarelto$149$227,713165 claims
AstraZenecaFarxiga, Brilinta$381$157,438142 claims
Boehringer IngelheimJardiance$48$94,81568 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,112 nurse practitioner providers in New York.

Other nurse practitioner in West Islip

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →